Despite the introduction of newly developed drugs such as lenalidomide and bortezomib, patients with multiple myeloma are still difficult to treat and have a poor prognosis. In order to find novel drugs that are effective for multiple myeloma, we tested the antitumor activity of 29 phthalimide derivatives against several multiple myeloma cell lines. Among these derivatives, 2-(2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3- dione (TC11) was found to be a potent inhibitor of tumor cell proliferation and an inducer of apoptosis via activation of caspase-3, 8 and 9. This compound also showed in vivo activity against multiple myeloma cell line KMS34 tumor xenografts in ICR/SCID mice. By means of mRNA display selection on a microfluidic chip, the target protein of TC11 was identified as nucleophosmin 1 (NPM). Binding of TC11 and NPM monomer was confirmed by surface plasmon resonance. Immunofluorescence and NPM knockdown studies in HeLa cells suggested that TC11 inhibits centrosomal clustering by inhibiting the centrosomal-regulatory function of NPM, thereby inducing multipolar mitotic cells, which undergo apoptosis. NPM may become a novel target for development of antitumor drugs active against multiple myeloma.
References
[1]
Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe. Ann Oncol 16: 481–488.
[2]
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585–598.
[3]
Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, et al. (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 11: 1086–1095.
[4]
Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, et al. (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208: 1680–1685.
[5]
Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, et al. (2002) Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 118: 1041–1047.
[6]
Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98: 2229–2238.
[7]
Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, et al. (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myeloma. Blood 109: 3489–3495.
[8]
Palumbo A, Larocca A, Falco P, Sanpaolo G, Falcone AP, et al. (2010) Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia 24: 1037–1042.
[9]
Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, et al. (2003) Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17: 427–436.
[10]
Stewart A, Fonseca R (2005) Prognostic and therapeutic significance or myeloma genetics and gene expression profiling. J Clin Oncol 23: 6339–6344.
[11]
Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, et al. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109: 2276–2284.
[12]
Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, et al. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943–2950.
[13]
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, et al. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutics implications. Blood 99: 4525–4530.
[14]
Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, et al. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109: 465–470.
[15]
Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha, Attal M, et al. (2010) Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 24: 623–628.
[16]
Miyamoto-Sato E, Takashima H, Fuse S, Sue K, Ishizaka M, et al. (2003) Highly stable and efficient mRNA templates for mRNA-protein fusions and C-terminal labeled proteins. Nucleic Acids Res 31: e78.
[17]
Zatsepina OV, Rousselet A, Chan PK, Olson MO, Jordan EG, et al. (1999) The nucleolar phosphoprotein B23 redistributes in part to the spindle poles during mitosis. J Cell Sci 112: 455–466.
[18]
Okuwaki M (2008) The structure and functions of NPM1/Nucleophosmin/B23, a multifunctional nucleolar acidic protein. J Biochem 143: 441–448.
[19]
Grisendi S, Mecucci C, Falini B, Pandolfi PP (2006) Nucleophosmin and cancer. Nat Rev Cancer 6: 493–505.
[20]
Okuda M (2002) The role of nucleophosmin in centrosome duplication. Oncogene 21: 6170–6174.
[21]
Saunders W (2005) Centrosomal amplification and spindle multipolarity in cancer cells. Semin. Cancer Biol 15: 25–32.
[22]
Li Z, Boone D, Hann SR (2008) Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Proc Natl Acad Sci U S A 105: 18794–18799.
[23]
Colombo E, Marine JC, Danovi D, Falini B, Giuseppe P (2002) Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 4: 529–533.
[24]
Rubbi CP, Milner J (2003) Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J 22: 6068–6077.
[25]
Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, et al. (2004) Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5: 465–475.
[26]
Quintyne NJ, Reing JE, Hoffelder DR, Gollin SM, Saunders WS (2005) Spindle multipolarity is prevented by centrosomal clustering. Science 307: 127–129.
[27]
Rebacz B, Larsen TO, Clausen MH, Ronnest MH, Loffler H, et al. (2007) Identification of Griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Res 67: 6342–6350.
[28]
Ganem N, Godinho SA, Pellman D (2009) A mechanism linking extra centrosomes to chromosomal instability. Nature 460: 278–283.
[29]
Sohyris N, Harrison DJ (2005) p53 deficiency exacerbates pleiotropic mitotic defects, changes in nuclearity and polyploidy in transdifferentiating pancreatic acinar cells. Oncogene 24: 2184–2194.
[30]
Chan PK, Chan FY (1995) Nucleoophosmin/B23 (NPM) oligomer is a major and stable entity in HeLa cells. Biochim Biophys Acta 1262: 37–42.
[31]
Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, et al. (2008) NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene 27: 4210–4220.
[32]
Leber B, Maler B, Fuchs F, Chi J, Riffel P, et al. (2010) Proteins required for centrosome clustering in cancer cells. Sci Transl Med 2: 33ra38.
[33]
Amin MA, Matsunaga S, Uchiyama S, Fukui K (2008) Nucleophosmin is required for chromosome congression, proper mitotic spindle formation, and kinetochore-microtubule attachment in HeLa cells. FEBS Lett 582: 3839–3844.
[34]
Wang W, Budhu A, Forgues M, Wang XW (2005) Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome dupulication. Nat Cell Biol 7: 823–830.
[35]
Rousselet A (2009) Inhibiting Crm1 causes the formation of excess acentriolar spindle poles containing NuMA and B23, but does not affect centrosome numbers. Biol Cell 101: 679–693.
[36]
Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM (2004) NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5: 465–475.
[37]
Inatsuki S, Noguchi T, Miyachi H, Oda S, Iguchi T, et al. (2005) Tubulin-polymerization inhibitors derived from thalidomide. Bioorg Med Chem Lett 15: 321–325.
[38]
Magedov IV, Manpadi M, Evdokimov NM, Elias EM, Rozhkova E, et al. (2007) Antiproliferative and apoptosis inducing properties of pyrano[3,2-c]pyridones accessible by one-step multicomponent synthesis. Bioorg Med Chem Lett 17: 3872–3876.
[39]
Otsuki T, Yamada O, Yata K, Sakaguchi H, Kurebayashi J, et al. (1999) Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14) (q16.3;q32. 3) and FGFR3 translocation. Int J Oncol 15: 1205–1212.
[40]
Du W, Hattori Y, Yamada T, Matsumoto K, Nakamura T, et al. (2007) NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 109: 3042–3049.
[41]
Tabata N, Sakuma Y, Honda Y, Doi N, Takashima H, et al. (2009) Rapid antibody selection by mRNA display on a microfluidic chip. Nucleic Acids Res 37: e64.
[42]
Horisawa K, Tateyama S, Ishizaka M, Matsumura N, Takashima H, et al. (2004) In vitro selection of Jun-associated proteins using mRNA display. Nucleic Acids Res 32: e169.
